Standard Safety Procedure Before Therapeutic Administration of 223 Ra-Dichloride.
| Autor: | Marcondes Braga Ribeiro A; Nuclear Medicine Department, A.C. Camargo Cancer Center, São Paulo, Brazil., Nóbrega Pereira Lima E; Nuclear Medicine Department, A.C. Camargo Cancer Center, São Paulo, Brazil. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of nuclear medicine technology [J Nucl Med Technol] 2024 Sep 05; Vol. 52 (3), pp. 219-220. Date of Electronic Publication: 2024 Sep 05. |
| DOI: | 10.2967/jnmt.123.266434 |
| Abstrakt: | 223 Ra-dichloride is an α-emitter therapy approved for the treatment of castration-resistant prostate cancer with symptomatic bone metastases. 223 Ra-dichloride is the first targeted α-therapy for this indication with evidence of benefit in overall survival. The administration is intravenous, and extravasation can cause severe injuries such as tissue necrosis. To prevent this side effect, some procedures can be performed according to the guideline of the European Association of Nuclear Medicine. Ionizing radiation is a well-established risk factor for the development of cutaneous squamous cell carcinoma, but surprisingly there are few reports of local adverse effects related to extravasation of radiotherapies at the injection sites. Recently, a possible case of cutaneous cancer was observed after 223 Ra-dichloride extravasation. Methods: To complement the prevention of extravasation, we developed a standardized technique to be performed before the injection of 223 Ra. Results: Our technique was successfully applied to the study population, and no apparent extravasation was seen. Conclusion: Our study suggests that use of this standardized technique before administration of 223 Ra is helpful in preventing extravasation during this treatment. (© 2024 by the Society of Nuclear Medicine and Molecular Imaging.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|